Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078442 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00078442 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants.
The verdict
NCT00078442, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Recombinant interferon (IFN) may be useful in the treatment of HIV. However, the high doses of IFN necessary to keep HIV under control limit its use due to toxic side effects. The purpose of this study is to test the safety and tolerability of weekly recombinant pegylated interferon (PEG-IFN) alfa-2a in HIV infected people who are currently on antiretroviral therapy (ART) interruption or who have not started taking anti-HIV drugs.
Interventions
- DRUG Pegylated interferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00078442
The ClinicalTrials.gov registry entry for NCT00078442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegylated interferon alfa-2a is the first listed.
NCT00078442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00078442 about?
NCT00078442 is a clinical study titled "Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People". Recombinant interferon (IFN) may be useful in the treatment of HIV. However, the high doses of IFN necessary to keep HIV under control limit its use due to toxic side effects. The purpose of this study is to test the safety and tolerability of weekly recombinant pegylated interferon (PEG-IFN) alfa-2...
What is the current status of trial NCT00078442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00078442?
The interventions under investigation include: Pegylated interferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT00078442?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.